CIRIUM
1.9.2022 10:01:34 CEST | Business Wire | Press release
The major US carriers made a clean sweep of the top four places as aviation analytics firm Cirium revealed its World Airline Passenger Rankings for 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220831005886/en/
US majors take top spot while low-cost carriers rise up the Cirium global airlines rankings. (Graphic: Business Wire)
American Airlines stays on top of the ranking again in 2021, followed by Delta Air Lines, United Airlines and Southwest Airlines, demonstrating the strength of the recovery that continues to take place in the US domestic market.
Overall, airlines in North America showed 75% growth from the low point in 2020, although still ending last year down by 40% on 2019 traffic levels, as measured in Revenue Passenger Kilometers/Miles (RPKs/RPMs).
The ranking, which is based on over 600 operators tracked in the Cirium airline database, shows that world traffic ended 2021 down by 57% against the pre-pandemic peak. In terms of passenger numbers, the total stood at 2.3 billion for the year, representing around half of the volumes from the peak in 2019.
Low-cost carriers continued to rise up the rankings across the regions. Ryanair cemented its place as Europe’s largest carrier, sitting in fifth place just below Southwest, and was the only European airline to make it into the top 10.
Europe’s major network carriers have fared less well over the past couple of years, as demand for long-haul, premium travel remained depressed. Although Air France held steady at 13th place, Lufthansa slipped down the rankings and British Airways fell out of the top 20 altogether. Virgin Atlantic also dropped more than 50 places as it too suffered from the slow return of long-haul and premium traffic.
The big three carriers in mainland China – China Southern, China Eastern and Air China – held their place toward the top of the ranking, although that could change after a renewed round of COVID-19 lockdowns in Chinese cities so far this year.
Across Asia Pacific as a whole – in stark contrast to recovery in all other world regions – airlines saw traffic fall again last year. Cathay Pacific slipped spectacularly, falling out of the top 100 ranking entirely following Hong-Kong’s pursuit of an aggressive zero-COVID strategy. It was not alone. Carriers across the region in Indonesia, Malaysia, South Korea and Thailand also continued to shrink.
In Japan, All Nippon Airways and Japan Airlines had lost nearly 85% of their traffic in 2020 and were still down by around 75% by the end of 2021. Both fell steeply down the rankings as a result.
Jeremy Bowen, Cirium CEO, said: “Pre-pandemic, Asia Pacific airlines held the single largest share of global passenger traffic, with over a third of the world total. By 2021 the region was overtaken by North America, led by the strong recovery in domestic US flying.”
Two Gulf carriers, Emirates and Qatar Airways, both retained their position within the top 10 airlines, although the gap between them narrowed. Emirates slipped four places to sit just ahead of a rising Qatar Airways, which has made a point of maintaining as much of its network as possible.
Turkish Airlines, helped by an extensive domestic market free of cross-border travel restrictions, climbed four places to 10th in the latest ranking compared with 2019.
The Cirium ranking highlights the struggle which mainline carriers have faced, especially those relying on a strong mix of business travel and long-haul flying. By 2021 their share of world passenger traffic had slipped some five percentage points to 64%. That decline was largely picked up by low-cost carriers, who raised their share to 26%.
Cirium’s World Airline Passenger Ranking 2021 is a premium analysis available in Cirium Dashboard. The report features:
- The Top 200 airlines by passenger traffic
- The Top 50 airline groups by passenger traffic
- The Top 50 airlines by passenger volume
- Passenger traffic by region and by airline type 2019-2021
- Share of passenger traffic by airline region and airline type
- Share of passenger volume by airline type
Click here to download the full report.
Ends
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
For further information please follow Cirium updates on LinkedIn or Twitter or visit www.cirium.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220831005886/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
